Ling Li

Ling Li

Auto-generated profile, based on publicly available information

Ling Li

Sichuan Key Laboratory of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
XYXinfang Yu
Xinfang Yu
WLWei Li
Wei Li
QDQipan Deng
Qipan Deng
HLHaidan Liu
Haidan Liu
XWXu Wang
Xu Wang
Yong LiYong Li
Yong Li
Myeloid differentiation primary response protein 88 (MYD88) is a critical universal adapter that transduces signaling from Toll-like and interleukin receptors to downstream nuclear factor-κB (NF-κB). MYD88L265P (leucine changed to proline at position 265) is a gain-of-function mutation that occurs frequently in B-cell malignancies such as Waldenstrom macroglobulinemia. In this study, E3 ligase RING finger protein family 138 (RNF138) catalyzed K63-linked nonproteolytic polyubiquitination of MYD88L265P, resulting in enhanced recruitment of interleukin-1 receptor–associated kinases and elevated NF-κB activation. However, RNF138 had little effect on wild-type MYD88 (MYD88WT). With either RNF138 knockdown or mutation on MYD88 ubiquitination sites, MYD88L265P did not constitutively activate NF-κB. A20, a negative regulator of NF-κB signaling, mediated K48-linked polyubiquitination of RNF138 for proteasomal degradation. Depletion of A20 further augmented MYD88L265P-mediated NF-κB activation and lymphoma growth. Furthermore, A20 expression correlated negatively with RNF138 expression and NF-κB activation in lymphomas with MYD88L265P and in those without. Strikingly, RNF138 expression correlated positively with NF-κB activation in lymphomas with MYD88L265P, but not in those without it. Our study revealed a novel mutation-specific biochemical reaction that drives B-cell oncogenesis, providing a therapeutic opportunity for targeting oncogenic MYD88L265P, while sparing MYD88WT, which is critical to innate immunity.

7 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
QDQipan Deng
Qipan Deng
HHHui Hu
Hui Hu
XYXinfang Yu
Xinfang Yu
SLShuanglin Liu
Shuanglin Liu
LWLei Wang
Lei Wang
Yong LiYong Li
Yong Li
A noncoding polymorphism (rs78378222) in TP53, carried by scores of millions of people, was previously associated with moderate risk of brain tumors and other neoplasms. We find a positive association between this variant and soft tissue sarcoma. In sharp contrast, it is protective against breast cancer. We generated a mouse line carrying this variant and found that it accelerates spontaneous tumorigenesis and glioma development, but strikingly, delays mammary tumorigenesis. The variant creates a miR-382-5p targeting site and compromises a miR-325-3p site. Their differential expression results in p53 downregulation in the brain, but p53 upregulation in the mammary gland of polymorphic mice compared to that of wild-type littermates. Thus, this variant is at odds with Li-Fraumeni Syndrome mutants in breast cancer predisposition yet consistent in glioma predisposition. Our findings elucidate an underlying mechanism of cancer susceptibility that is conferred by genetic variation and yet altered by microRNA expression.

28 June 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XWXu Wang
Xu Wang
XYXinfang Yu
Xinfang Yu
WLWei Li
Wei Li
PNPraveen Kumar Neeli
Praveen Kumar Neeli
MLMing Liu
Ming Liu
Yong LiYong Li
Yong Li
Background: Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. The high expression of CD38 across MM and other lymphoid malignancies and its restricted expression in normal tissues make CD38 an attractive target for immunotherapy. CD38-targeting antibodies, like daratumumab, have been approved for the treatment of MM and tested against lymphoma and leukemia in multiple clinical trials. Methods: We generated chimeric antigen receptor (CAR) T cells targeting CD38 and tested its cytotoxicity against multiple CD38high and CD38low lymphoid cancer cells. We evaluated the synergistic effects of all-trans retinoic acid (ATRA) and CAR T cells or daratumumab against cancer cells and xenograft tumors. Results: CD38-CAR T cells dramatically inhibited the growth of CD38high MM, mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia (WM), T-cell acute lymphoblastic leukemia (T-ALL), and NK/T-cell lymphoma (NKTCL) in vitro and in mouse xenografts. ATRA elevated CD38 expression in multiple CD38low cancer cells and enhanced the anti-tumor activity of daratumumab and CD38-CAR T cells in xenograft tumors. Conclusions: These findings may expand anti-CD38 immunotherapy to a broad spectrum of lymphoid malignancies and call for the incorporation of ATRA into daratumumab or other anti-CD38 immunological agents for cancer therapy.

27 June 2025 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
ZTZhihao Tu
Zhihao Tu
YCYuelin Chen
Yuelin Chen
ZZZhimi Zhang
Zhimi Zhang
WMWanrong Meng
Wanrong Meng
LLLing Li
Ling Li

3 June 2019 in Biomarkers in Medicine
Verified
Journal Article
Open access
YZYangying Zhou
Yangying Zhou
NHNaseruddin Höti
Naseruddin Höti
MAMinghui Ao
Minghui Ao
ZZZhen Zhang
Zhen Zhang
HZHong Zhu
Hong Zhu
QLQing Kay Li
Qing Kay Li
Aim: p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung...

1 October 2014 in Journal of Cardiology
Verified
Journal Article
Closed access
XXXu-Dong Xu
Xu-Dong Xu
SLSuxuan Liu
Suxuan Liu
XLXin Liu
Xin Liu
YCYan Chen
Yan Chen
LLLing Li
Ling Li
YQYong-Wen Qin
Yong-Wen Qin